Applied Therapeutics reports Q1 EPS (15c), consensus (18c)

Cash and cash equivalents and short-term investments totaled $50.8M as of March 31, compared with $79.4M at December 31, 2024. “We continue to focus on executing against our operational, regulatory and clinical goals and are pleased to be in a stronger position across these strategies with a focus on the advancement of govorestat across multiple indications. We remain confident in the potential of govorestat to address the high unmet needs of patients with rare diseases and continue to prepare for potential future regulatory interactions for both CMT-SORD and Classic Galactosemia. With a strong team in place, we believe we are well poised to address these priorities,” said Les Funtleyder, Interim CEO and CFO of Applied Therapeutics (APLT). “In the near-term, our team looks forward to presenting full 12-month clinical data from the Phase 3 INSPIRE study in CMT-SORD deficiency at the upcoming PNS Annual Meeting in addition to sharing new topline 18 and 24 month data from patients prior to transition to the open label extension study.”